U.S. Treasury wants to rein in deals for Chinese biotech and AI
FROM THE WIRE · FINANCE.YAHOO.COM
The prohibitions could cut off Big Pharma from Chinese biotechs—the source of many promising cancer treatments Continue Reading
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe restrictions could cut big pharma off from Chinese biotechs, weighing on the pharma sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The U.S. Treasury is weighing prohibitions on deals with Chinese biotechs.
- 02Chinese biotechs are the source of many promising cancer treatments.
- 03The prohibitions could cut big pharma off from these deals.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
AstraZeneca PLC172.57 USDMarket closedtoday +2.45%Negative Merck & Co., Inc.147.24 USDMarket closedtoday -1.76%Negative Pfizer Inc.30.42 USDMarket closedtoday +1.91%Negative
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets